Back to Newsroom

Corbus Pharmaceuticals Reports Positive Topline Results from Phase 2 Study in Rare Autoimmune Disease Dermatomyositis

NORWOOD, MA — (Marketwired) — 10/19/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced positive topline results from its 16-week Phase 2 study of safety and efficacy of anabasum in dermatomyositis (“DM”).